{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T12:22:09Z","timestamp":1777638129352,"version":"3.51.4"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.intimp.2023.110050","type":"journal-article","created":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T20:04:48Z","timestamp":1680206688000},"page":"110050","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["The efficacy and safety of dupilumab combined with methylprednisolone in the treatment of bullous pemphigoid in China"],"prefix":"10.1016","volume":"118","author":[{"given":"Wang","family":"Qi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Rushan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2023.110050_b0005","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.912876","article-title":"Insights Into the Pathogenesis of Bullous Pemphigoid: The Role of Complement-Independent Mechanisms","volume":"13","author":"Cole","year":"2022","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2023.110050_b0010","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jaad.2020.01.089","article-title":"Dupilumab as a novel therapy for bullous pemphigoid: A multicenter case series","volume":"83","author":"Abdat","year":"2020","journal-title":"J Am Acad Dermatol."},{"issue":"12","key":"10.1016\/j.intimp.2023.110050_b0015","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.3390\/jcm11123528","article-title":"Current and Innovated Managements for Autoimmune Bullous Skin Disorders: An Overview","volume":"11","author":"Chu","year":"2022","journal-title":"J Clin Med."},{"issue":"12","key":"10.1016\/j.intimp.2023.110050_b0020","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1111\/1346-8138.15111","article-title":"Japanese guidelines for the management of pemphigoid (including epidermolysis bullosa acquisita)","volume":"46","author":"Ujiie","year":"2019","journal-title":"J Dermatol."},{"issue":"3","key":"10.1016\/j.intimp.2023.110050_b0025","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jaad.2011.06.032","article-title":"Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts","volume":"66","author":"Murrell","year":"2012","journal-title":"J Am Acad Dermatol."},{"issue":"7","key":"10.1016\/j.intimp.2023.110050_b0030","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1111\/jdv.16363","article-title":"Anti-BP180 autoantibody levels at diagnosis correlate with 1-year mortality rates in patients with bullous pemphigoid","volume":"34","author":"Monshi","year":"2020","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"5","key":"10.1016\/j.intimp.2023.110050_b0035","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1111\/bjd.15649","article-title":"An open, multicentre, randomized clinical study in patients with bullous pemphigoid comparing methylprednisolone and azathioprine with methylprednisolone and dapsone","volume":"177","author":"Sticherling","year":"2017","journal-title":"Br J Dermatol."},{"issue":"2","key":"10.1016\/j.intimp.2023.110050_b0040","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1080\/08820139.2020.1832113","article-title":"Association between TH2 Cytokine Gene Polymorphisms and Risk of Bullous Pemphigoid","volume":"51","author":"Tabatabaei-Panah","year":"2022","journal-title":"Immunol Invest."},{"issue":"10","key":"10.1016\/j.intimp.2023.110050_b0045","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1001\/jamadermatol.2018.2526","article-title":"Dupilumab for the Treatment of Recalcitrant Bullous Pemphigoid","volume":"154","author":"Kaye","year":"2018","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.intimp.2023.110050_b0050","article-title":"Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2023.110050_b0055","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/ajd.13692","article-title":"Dupilumab successfully treated refractory bullous pemphigoid with early clinical manifestations imitating atopic dermatitis: A case letter","volume":"62","author":"Zhang","year":"2021","journal-title":"Australas J Dermatol."},{"key":"10.1016\/j.intimp.2023.110050_b0060","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jdcr.2021.09.014","article-title":"Nonbullous erythrodermic pemphigoid with florid lymphadenopathy, response to dupilumab","volume":"17","author":"Bal","year":"2021","journal-title":"JAAD Case Rep."},{"key":"10.1016\/j.intimp.2023.110050_b0065","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.611549","article-title":"Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid","volume":"11","author":"Seyed Jafari","year":"2021","journal-title":"Front Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2023.110050_b0070","doi-asserted-by":"crossref","first-page":"e2021144","DOI":"10.5826\/dpc.1104a144","article-title":"The New Era of Biologics in Atopic Dermatitis: A Review","volume":"11","author":"Schneider","year":"2021","journal-title":"Dermatol Pract Concept."},{"issue":"1","key":"10.1016\/j.intimp.2023.110050_b0075","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/12034754211027858","article-title":"Prominent Role of Type 2 Immunity in Skin Diseases: Beyond Atopic Dermatitis","volume":"26","author":"Belmesk","year":"2022","journal-title":"J Cutan Med Surg."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923003715?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923003715?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:48:08Z","timestamp":1761587288000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576923003715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":15,"alternative-id":["S1567576923003715"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2023.110050","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The efficacy and safety of dupilumab combined with methylprednisolone in the treatment of bullous pemphigoid in China","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2023.110050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110050"}}